ArticleBioMed research international2026
Promising Potential of Edaravone-Loaded Nanogel in Ameliorating of Stroke in Rats: The Modulation of Immune Response.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesIschemic stroke is mainly caused by the interruption of cerebral blood flow, which causes severe neurological damage and is one of the main drawbacks of death and disability worldwide. Edaravone (EDV) has been clinically used for the treatment of ischemic stroke in Japan and some countries with two major drawbacks: poor water solubility and nephrotoxicity. Therefore, GSH-PMAA or nanogel was utilized as a drug carrier for EDV to overcome this issue.
methodsThe study was designed to assess the cognitive response and expression of brain tissue genes, including heat-shock protein (Hsp70), Toll-like receptors (Tlr4&Tlr7), following treatment with EDV-loaded nanogel or GSH-PMAA-EDV in ischemic rats. Animals were randomly divided into seven groups, and after the induction of the ischemia-like model, rats received different doses of EDV-loaded nanogel.
resultsOn the day after the novel object recognition test, the rodent hippocampus was dissected and used for the evaluation of gene expression. Real-time PCR was used to evaluate the gene expression of Tlr4, Tlr7, and Hsp70. These results indicated that after the induction of stroke in animals, the expression of Tlr4 and Tlr7 increased significantly. However, no significant change in Hsp70 expression was observed. However, EDV-loaded nanogel at doses of 20, 40, and, 250 μg/kg restored the overexpression of Tlr4 and Tlr7.
conclusionTreatment with EDV-loaded nanogel has been shown to improve cognitive behavior and immune response of neural tissue in a transient global ischemic model. These improvements were also achieved at lower equalized doses when compared with the unmodified EDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.